HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation

Journal of Leukocyte Biology

C. L. Lucas⁴  M. L. del Rio¹  G. Rayat²  L. Buhler³  J. I. Rodriguez-Barbosa¹ 

[1] Laboratory of Immunobiology, Institute of Biomedicine, Campus de Vegazana s/n, Leon, Spain; Laboratory of Immunobiology, Institute of Biomedicine, Campus de Vegazana s/n, Leon, Spain; Laboratory of Immunobiology, Institute of Biomedicine, Campus de Vegazana s/n, Leon, Spain;;Alberta Diabetes Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada Alberta Diabetes Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada Alberta Diabetes Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada;Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Surgical Research Unit, Department of Surgery, University Hospital Geneva, Geneva, Switzerland; and Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Surgical Research Unit, Department of Surgery, University Hospital Geneva, Geneva, Switzerland; and Surgical Research Unit, Department of Surgery, University Hospital Geneva, Geneva, Switzerland; and Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Surgical Research Unit, Department of Surgery, University Hospital Geneva, Geneva, Switzerland; andBone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA;

关键词: coinhibition;    costimulation;    transplantation;    autoimmunity;   

DOI  :  10.1189/jlb.0809590

学科分类：生理学

来源: Federation of American Societies for Experimental Biology

【 摘 要 】

Abstract Immunosuppression is currently the treatment of choice to attenuate the chronic deterioration of tissue function as a result of the effector mechanisms of the immunological response in transplant rejection and autoimmune diseases. However, global immunosuppression greatly increases the risk of acquiring life-threatening infections and is associated with organ toxicity when used long-term. Thus, alternative approaches that inhibit only the unwanted immune responses and preserve general immunity are highly desirable. The receptor/ligand pairs involved in the cross-talk between DC and T cells have been the focus of intense and exciting research during the last decade. The HVEM/LIGHT/BTLA/CD160 costimulatory/coinhibitory pathway has emerged as a potential target for the development of immune therapeutic interventions. Herein, we will summarize and discuss how blockade of the costimulatory HVEM/LIGHT interaction or agonist signaling through the inhibitory BTLA and CD160 receptors could contribute to the control of deleterious immune responses.

【 授权许可】

Unknown